The vitreous substitute for proliferative vitreoretinopathy (PVR) surgery remains an unmet clinical need in ophthalmology. In our study, we developed an in situ formed hydrogel by crosslinking polyvinyl alcohol (PVA) and chitosan as a potential vitreous substitute. 5‐fluorouracil (5‐FU) Poly (lactic‐co‐glycolic acid) (PLGA) microspheres were developed and loaded onto the PVA/chitosan hydrogels to treat PVR. In vitro, PVA/chitosan hydrogels at four concentrations were subjected to morphological, physical, rheological analyses, and cytotoxicity was evaluated together with the characterization of 5‐FU PLGA microspheres. In vivo, pharmacologically induce PVR rabbits were performed a vitrectomy. In the PVA group, 3% PVA/chitosan hydrogel was injected into the vitreous cavity. In the PVA/MS group, 3% PVA/chitosan hydrogel and 5‐FU PLGA microspheres were injected. In the Control group, phosphate‐buffered saline was injected. Therapeutic efficacy was evaluated with postoperative examinations and histological analyses. This study demonstrated that the 3% PVA/chitosan hydrogel showed properties similar to those of the human vitreous and could be a novel in situ crosslinked vitreous substitute for PVR. Loading 5‐FU PLGA microspheres onto this hydrogel may represent an effective strategy to improve the prognosis of PVR.

中文翻译：

---

载有 5-FU PLGA 微球的自组装水凝胶作为增殖性玻璃体视网膜病变的新型玻璃体替代品。

增殖性玻璃体视网膜病变 (PVR) 手术的玻璃体替代物仍然是眼科未满足的临床需求。在我们的研究中，我们通过交联聚乙烯醇 (PVA) 和壳聚糖作为潜在的玻璃体替代品开发了一种原位形成的水凝胶。5-氟尿嘧啶（5-FU）聚（乳酸-乙醇酸共聚物）（PLGA）微球被开发并加载到PVA/壳聚糖水凝胶上以治疗PVR。在体外，对四种浓度的 PVA/壳聚糖水凝胶进行形态学、物理、流变学分析，并与 5-FU PLGA 微球的表征一起评估细胞毒性。在体内，对药理学诱导的 PVR 兔进行玻璃体切除术。PVA组玻璃体腔内注射3%PVA/壳聚糖水凝胶。在 PVA/MS 组中，注射 3% PVA/壳聚糖水凝胶和 5-FU PLGA 微球。对照组注射磷酸盐缓冲液。通过术后检查和组织学分析评估治疗效果。该研究表明，3% PVA/壳聚糖水凝胶显示出与人类玻璃体相似的特性，可能是 PVR 的新型原位交联玻璃体替代品。将 5-FU PLGA 微球负载到这种水凝胶上可能是改善 PVR 预后的有效策略。该研究表明，3% PVA/壳聚糖水凝胶显示出与人类玻璃体相似的特性，可能是 PVR 的新型原位交联玻璃体替代品。将 5-FU PLGA 微球负载到这种水凝胶上可能是改善 PVR 预后的有效策略。该研究表明，3% PVA/壳聚糖水凝胶显示出与人类玻璃体相似的特性，可能是 PVR 的新型原位交联玻璃体替代品。将 5-FU PLGA 微球负载到这种水凝胶上可能是改善 PVR 预后的有效策略。